Proposed Protocol for the Evaluation of the Effect of High Purity Factor Concentrates on the Immune System of Hemophilia Patients

• References

• 1 Carr R, Edmund E, Prescott RJ, Veitch SE, Peutherer JF, Steel CM, Ludlam CA. Abnormalities of circulating lymphocyte subsets in haemophiliacs in an AIDS-free population. Lancet 1984; 1: 1431-1434
• 2 Aledort LM. Blood products and immune changes: Impacts without HIV infection. Semin Hematol 1988; 25: 14-20
• 3 Schreiber AB. The preclinical characterization of Monoclate® Factor VIII :C antihemophilic factor (human). Semin Hematol 1988; 25: 27-33
• 4 Eibl MM, Ahmad R, Wolf VM, Linnau Y, Gotz E, Mannhaber JW. A component of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions. Blood 1987; 69: 1153-1160
• 5 Margolick JB, Volkman OJ, Folks TM, Fauci AS. Amplification of HTLV-III/LAV infection by antigen induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. J Immunol 1987; 138: 1719-1728
• 6 Folks TM, Justement J, Kinter A, Dinerello CA, Fauci AS. Cytotoxic induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238: 800-821
• 7 Mosca JD, Bednarik DP, Raj NB, Rosen CA, Sodroski JG, Haseltine WA, Pitha PM. Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature 1987; 325: 67-70